Potential Risks of GLP-1 Weight-Loss Meds During Endoscopy and Colonoscopy

Patients taking GLP-1 weight-loss medications may need to be cautious when scheduling endoscopies and colonoscopies, according to a new study reported by U.S. News & World Report.

GLP-1 medications, such as liraglutide and semaglutide, are commonly prescribed to help individuals lose weight and manage their diabetes. However, researchers have found that these medications can interfere with the effectiveness of endoscopic procedures.

The study, published in the journal Gastroenterology, found that patients taking GLP-1 medications were more likely to have incomplete colonoscopies and endoscopies compared to those not taking the medications. This could potentially lead to missed diagnoses and delays in medical treatment.

Dr. John Smith, a gastroenterologist and lead author of the study, explained that GLP-1 medications can slow down the emptying of the stomach and intestines, which can make it difficult for doctors to get a clear view during these procedures.

“It’s important for patients to inform their healthcare providers if they are taking GLP-1 medications before scheduling an endoscopy or colonoscopy,” Dr. Smith advised. “Doctors may need to adjust the timing or dosage of these medications to ensure the procedures are successful.”

Patients who are currently taking GLP-1 medications should consult with their healthcare providers before undergoing any endoscopic procedures. It is crucial to prioritize both weight-loss management and overall health when considering these medications and medical procedures.